Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling.
Vin H, Ojeda SS, Ching G, Leung ML, Chitsazzadeh V, Dwyer DW, Adelmann CH, Restrepo M, Richards KN, Stewart LR, Du L, Ferguson SB, Chakravarti D, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Kim KB, Ciurea AM, Duvic M, Prieto VG, Ullrich SE, Dalby KN, Flores ER, Tsai KY. Vin H, et al. Among authors: tsai ky. Elife. 2013 Nov 5;2:e00969. doi: 10.7554/eLife.00969. Elife. 2013. PMID: 24192036 Free PMC article.
Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
Pattanaprichakul P, Tetzlaff MT, Lapolla WJ, Torres-Cabala CA, Duvic M, Prieto VG, Tsai KY, Curry JL. Pattanaprichakul P, et al. Among authors: tsai ky. J Cutan Pathol. 2014 Mar;41(3):326-8. doi: 10.1111/cup.12273. Epub 2013 Dec 24. J Cutan Pathol. 2014. PMID: 24372055 No abstract available.
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Vin H, et al. Among authors: tsai ky. Mol Cancer Ther. 2014 Jan;13(1):221-9. doi: 10.1158/1535-7163.MCT-13-0561. Epub 2013 Oct 29. Mol Cancer Ther. 2014. PMID: 24170769 Free PMC article.
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Fowler NH, et al. Among authors: tsai ky. Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439689 Free PMC article. Clinical Trial.
237 results